跳至主要内容
临床试验/EUCTR2013-005487-26-IT
EUCTR2013-005487-26-IT进行中(未招募)1 期

A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on aBackbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults - Dose-finding study of BMS-955176 in HIV-1 Infected treatment-naive

BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO0 个研究点目标入组 300 人开始时间: 2018年2月21日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Men and non-pregnant women, at least 18 years of age
  • - Antiretroviral treatment-naïve; defined as no current or previous
  • exposure to > 1 week of an antiretroviral drug
  • Plasma HIV-1 RNA > or = to 1000 copies/mL
  • - CD4 T-cell count > 200 cells/mm3
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 1
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 278
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 22

排除标准

  • - Resistance or partial resistance to any study drug determined by tests
  • at Screening
  • - Current or historical genotypic and/or phenotypic drug resistance
  • testing showing certain resistance mutations to EFV, TDF, FTC, Protease
  • Inhibitors, (Please see protocol for further information on these
  • exclusionary mutations)
  • - Chronic HBV/HCV
  • - Blood tests that inidcate normal liver function (see protocol)
  • - Hemoglobin < 8.0 g/dL and Platelets < 50,000 cells/mm3

研究者

相似试验